The European Medicines Agency (EMA) has started a review of Lemtrada (alemtuzumab) following reports of side effects affecting the heart, blood vessels, liver and immune system. These side effects are rare but potentially serious.
As a temporary measure while the review is being carried out, the EMA has advised that Lemtrada should only be started in people with relapsing remitting MS that continues to be very active despite taking at least two disease modifying drugs (DMDs) or where other DMDs cannot be taken.
If you have already started Lemtrada and are due to receive further infusions, you should continue with treatment. Anyone who has been treated with Lemtrada should continue to have monthly blood and urine tests for four years after the last treatment course.
If you have concerns, you should talk to your neurologist or MS nurse.
Move it for MS Nick's story
7 Oct 2021 - 00:00
Nick, was diagnosed with relapsing remitting multiple sclerosis at the start of the first lockdown. In this story we talk to him about how he coped with his diagnosis and how running helps him with his MS.
David's diary - Inclusion and diversity, where are we now?
6 Oct 2021 - 00:00
Just over a year ago we published a diary entry about Inclusivity and Diversity at the MS Trust. In this piece we take a look at what's changed since then and what we still need to do.
Flu season 2021
4 Oct 2021 - 00:00
This year is likely to involve a bigger flu vaccination programme in the UK, including for people with multiple sclerosis (MS), due to the circulation of Covid-19 at the same time. Here we discuss who's eligible for a flu jab on the NHS and how to get one.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.